Article Information
History
- March 12, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Sibonakaliso Vilakati1,*,
- Nontokozo Mngadi2,*,
- Jade Benjamin-Chung3,4,*,
- Nomcebo Dlamini1,
- Mi-Suk Kang Dufour3,5,
- Brooke Whittemore6,
- Khayelihle Bhangu1,
- Lisa M. Prach4,
- Kimberly Baltzell7,
- Nomcebo Nhlabathi1,
- Calisile Malambe1,
- Bongani Dlamini2,
- Danica Helb5,
- Bryan Greenhouse5,
- Gugu Maphalala8,
- Deepa Pindolia2,
- Muhindo Kalungero9,
- Getahun Tesfa10,
- Roly Gosling4,
- Nyasatu Ntshalintshali2,
- Simon Kunene1,‡ and
- Michelle S. Hsiang4,6,11,†
- 1Eswatini National Malaria Program, Manzini, Eswatini
- 2Clinton Health Access Initiative, Mbabane, Eswatini
- 3Division of Epidemiology & Biostatistics, University of California, Berkeley, USA
- 4Malaria Elimination Initiative, Global Health Group, UCSF
- 5Department of Medicine, University of California, San Francisco (UCSF), USA
- 6Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, USA
- 7Department of Family Health Care Nursing, UCSF
- 8Department of Medicine National Clinical Laboratory Services, Mbabane, Eswatini
- 9Good Shepherd Hospital, Siteki, Eswatini
- 10Raleigh Fitkin Memorial Hospital, Manzini, Eswatini
- 11Department of Pediatrics, UCSF
- ↵†Correspondence to: Michelle Hsiang MD MSc, Department of Pediatrics, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX, USA, +1-214-648-2228, michelle.hsiang{at}utsouthwestern.edu
↵* contributed equally
Posted March 12, 2021.
Effectiveness and safety of reactive focal mass drug administration (rfMDA) using dihydroartemisinin-piperaquine to reduce malaria transmission in very low-endemic setting of Eswatini: a pragmatic cluster randomised controlled trial
